Clinical trial
A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With…
NCT00090701 · Pfizer, Industry · Withdrawn
Key facts
| NCT number | NCT00090701 |
|---|---|
| Title | A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer |
| Official title | A Phase 2, Open-Label, Multicenter Study Of The GARFT Inhibitor AG2037 In Patients With MetastatIC Non Small Cell Lung Cancer Who Failed Two Or Three Prior Treatments |
| Lead sponsor | Pfizer, Industry |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Neoplasms |
| Intervention type | Drug |
| Interventions | AG2037 |
| Enrollment | 0 |
| Start date | Sep 1, 2004 |
| First posted | Sep 6, 2004 |
| Last update posted | May 10, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: